### Misoprostol

**Indication** | Unspecified obstetric condition  
**INN** | Misoprostol  
**Medicine type** | Chemical agent  
**List type** | Core  
**Additional notes** | Only for use for induction of labour where appropriate facilities are available.  
**Formulations** | Local > Vaginal > tablet: 25 µg  
**EML status history** | First added in 2005 (TRS 933)  
Changed in 2011 (TRS 965)  
**Sex** | Female  
**Age** | Adolescents and adults  
**Therapeutic alternatives** | The recommendation is for this specific medicine  
**Patent information** | Patents have expired in most jurisdictions  
Read more about patents.  
**Wikipedia** | Misoprostol  
**DrugBank** | Misoprostol

### Summary of evidence and Expert Committee recommendations

As part of the recommendation to include misoprostol 200 mcg oral tablets on the EML for the prevention of post-partum haemorrhage, the Expert Committee recommended moving misoprostol from the complementary to the core list, and the addition of a note for the 25 microgram vaginal tablet stating "Only for use for induction of labour where appropriate facilities are available."